Sonire Therapeutics Inc. is a clinical-stage medical device company pioneering sonic technology to treat cancer in a way that is not only more effective but less invasive for patients. The company's next-generation HIFU therapy system is designed to provide precise, non-invasive, outpatient treatment for solid tumors, beginning with pancreatic cancer. Founded in February 2020 in Tokyo and now headquartered in Palo Alto, CA, Sonire is committed to transforming oncology through innovative, patient-centered acoustic engineering.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/15/26	$18,000,000	Series A	Fast Track Initiative Nomura SPARX Investment Sante Ventures SBI Investments	undisclosed